Where Brands Lead, Rx Prices Follow
Managed care and pharmacy benefit management were supposed to drive drug prices down by creating customers with enormous leverage. But a recent study of pricing by Express Scripts, a PBM, suggests that where a drug company has a strong franchise with a leading brand, managed care is relatively powerless to drive discounts.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.